Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
Fractyl Health (NASDAQ:GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes, has scheduled two important investor events. The company will release its Q2 2025 financial results and provide business updates on August 12, 2025, at 4:30 p.m. ET.
Additionally, CEO Harith Rajagopalan will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 11:30 a.m. ET. Both events will be accessible via webcast through the company's investor relations website.
Fractyl Health (NASDAQ:GUTS), un'azienda specializzata in terapie metaboliche per il trattamento dell'obesità e del diabete di tipo 2, ha programmato due eventi importanti per gli investitori. La società pubblicherà i suoi risultati finanziari del secondo trimestre 2025 e fornirà aggiornamenti aziendali il 12 agosto 2025 alle 16:30 ET.
Inoltre, l'amministratore delegato Harith Rajagopalan parteciperà alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity il 13 agosto 2025 alle 11:30 ET. Entrambi gli eventi saranno disponibili in webcast tramite il sito web delle relazioni con gli investitori della società.
Fractyl Health (NASDAQ:GUTS), una empresa terapéutica metabólica especializada en tratamientos para la obesidad y la diabetes tipo 2, ha programado dos eventos importantes para inversores. La compañía publicará sus resultados financieros del segundo trimestre de 2025 y ofrecerá actualizaciones comerciales el 12 de agosto de 2025 a las 4:30 p.m. ET.
Además, el CEO Harith Rajagopalan presentará en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity el 13 de agosto de 2025 a las 11:30 a.m. ET. Ambos eventos estarán disponibles vía webcast a través del sitio web de relaciones con inversores de la compañía.
Fractyl Health (NASDAQ:GUTS)는 비만 및 제2형 당뇨병 치료를 전문으로 하는 대사 치료 회사로, 두 가지 중요한 투자자 행사를 예정하고 있습니다. 회사는 2025년 2분기 재무 실적을 발표하고 2025년 8월 12일 오후 4시 30분(동부시간)에 사업 현황을 업데이트할 예정입니다.
또한, CEO 하리스 라자가팔란(Harith Rajagopalan)은 Canaccord Genuity 제45회 연례 성장 컨퍼런스에서 2025년 8월 13일 오전 11시 30분(동부시간)에 발표할 예정입니다. 두 행사 모두 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
Fractyl Health (NASDAQ:GUTS), une entreprise spécialisée dans les thérapies métaboliques pour le traitement de l'obésité et du diabète de type 2, a programmé deux événements importants pour les investisseurs. La société publiera ses résultats financiers du deuxième trimestre 2025 et fournira des mises à jour commerciales le 12 août 2025 à 16h30 ET.
De plus, le PDG Harith Rajagopalan présentera lors de la 45e conférence annuelle sur la croissance de Canaccord Genuity le 13 août 2025 à 11h30 ET. Les deux événements seront accessibles en webcast via le site web des relations investisseurs de la société.
Fractyl Health (NASDAQ:GUTS), ein Unternehmen für metabolische Therapien, das sich auf Behandlungen von Fettleibigkeit und Typ-2-Diabetes spezialisiert hat, hat zwei wichtige Investorenveranstaltungen geplant. Das Unternehmen wird seine Finanzergebnisse für das zweite Quartal 2025 veröffentlichen und am 12. August 2025 um 16:30 Uhr ET Geschäftsaktualisierungen geben.
Darüber hinaus wird CEO Harith Rajagopalan auf der 45. jährlichen Wachstumskonferenz von Canaccord Genuity am 13. August 2025 um 11:30 Uhr ET präsentieren. Beide Veranstaltungen sind per Webcast über die Investor-Relations-Website des Unternehmens zugänglich.
- None.
- None.
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET.
The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET.
A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 32 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA. For more information, visit www.fractyl.com.
Contacts
Media Contact
Jessica Cotrone, Head of Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
FAQ
When will Fractyl Health (GUTS) report Q2 2025 earnings?
Where can I watch Fractyl Health's Q2 2025 earnings call?
When is Fractyl Health presenting at the Canaccord Genuity Conference?
What is Fractyl Health's main business focus?
